Market Trends Influencing Strategic Decisions in the Huntington’s Disease Treatment Industry: Advancements In Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Therapies For Huntington’s Disease Treatment
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Huntington’s Disease Treatment Market Expected to Grow Between 2025 And 2029?
The market size for treatment of Huntington’s disease has seen a swift expansion in recent times, with a projected growth from $0.73 billion in 2024 to $0.82 billion in 2025, translating to a compound annual growth rate (CAGR) of 12.3%. This surge during the historic period can be linked to a heightened understanding of genetic disorders, enhanced accessibility to genetic testing, increased funding for research into neurodegenerative diseases, a higher prevalence of clinical trials testing experimental therapies, and a flourishing pipeline of disease-altering drugs.
The market size for Huntington’s disease treatment is projected to witness substantial growth in the forthcoming years, reaching $1.32 billion in 2029, with a compound annual growth rate (CAGR) of 12.6%. Factors contributing to the growth during the forecast period include an increasing emphasis on personalized medicine, greater integration of digital health monitoring, expanded regulatory support for orphan drugs, a surge in demand for symptomatic relief therapies, and increased demand for disease-modifying treatments. The forecast period will also see major trends such as the use of technology in gene-silencing tools, the advancement of cell-based therapies, the development of peripheral biomarkers, incorporation of telehealth in HD care, the inclusion of patient-reported outcomes, and innovative strides in disease-modifying drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Huntington’s Disease Treatment Market?
The rise in gene therapies is projected to boost the Huntington’s disease treatment market’s growth. Gene therapies, which alter or substitute faulty genes to prevent or cure diseases at the genetic level, are on the rise as precision medicine continues to advance. These therapies allow for the precise targeting of genetic causes, resulting in superior outcomes compared to traditional treatments. Gene therapies work to treat Huntington’s disease by muting the dysfunctional HTT gene that creates damaging proteins, thus preventing neuronal cell damage. This approach aids in slowing the disease’s progression, protecting brain functionality, and potentially providing long-term control. The American Society of Gene & Cell Therapy (ASGCT) for instance, alongside Citeline – both US-based, noted that as of July 2023, there were 247 gene therapies in phase II by the conclusion of Q1 2023, but this number experienced a 5% increase, amounting to 260 by Q2’s end. As such, the escalating numbers of gene therapies are fueling the growth of the market for Huntington’s disease treatment.
Which Key Market Segments Comprise the Huntington’s Disease Treatment Market and Drive Its Revenue Growth?
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp
Which Areas Are Leading Regions in the Huntington’s Disease Treatment Market Expansion Across the Globe?
North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theHuntington’s Disease Treatment Market Direction?
Leading enterprises in the Huntington’s disease treatment market are streamlining their focus towards introducing innovative therapy options like selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules. The aim is to considerably enhance the patient’s lifestyle while mitigating the progression of the disease. These capsules, by blocking the action of the vesicular monoamine transporter 2 protein that plays a pivotal role in packing neurotransmitters for releasing into the brain, significantly restrict the release of neurotransmitters. This aids in controlling involuntary movements and related symptoms. To provide a pertinent example, Neurocrine Biosciences, Inc., an American bio-technology firm, secured the U.S. FDA’s approval for Ingrezza (valbenazine) capsules in August 2023. The capsules, developed as treatment for chorea in adults suffering from Huntington’s disease (HD), function by limiting excessive dopamine signaling in the brain, thus regulating involuntary movements. The medication, available in various strengths of capsules and safe for consumption with or without food, stacks up as a convenient choice for patients.
View the full report here:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report
How Is the Huntington’s Disease Treatment Market Conceptually Defined?
Huntington’s disease treatment involves medical therapies designed to manage the symptoms of this progressive neurological disorder. The primary goal is to slow disease progression, alleviate symptoms, and enhance the patient’s quality of life.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24245
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
